The 36-month beta value for PASG is at 1.30. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for PASG is 41.17M, and currently, shorts hold a 3.21% of that float. The average trading volume for PASG on April 19, 2024 was 353.06K shares.
PASG) stock’s latest price update
The stock price of Passage Bio Inc (NASDAQ: PASG) has dropped by -3.41 compared to previous close of 1.20. Despite this, the company has seen a fall of -13.50% in its stock price over the last five trading days. Zacks Investment Research reported 2024-03-07 that Does Passage Bio, Inc. (PASG) have what it takes to be a top stock pick for momentum investors? Let’s find out.
PASG’s Market Performance
Passage Bio Inc (PASG) has seen a -13.50% fall in stock performance for the week, with a -24.24% decline in the past month and a 28.95% surge in the past quarter. The volatility ratio for the week is 8.56%, and the volatility levels for the past 30 days are at 9.67% for PASG. The simple moving average for the past 20 days is -12.24% for PASG’s stock, with a 24.60% simple moving average for the past 200 days.
Analysts’ Opinion of PASG
Goldman, on the other hand, stated in their research note that they expect to see PASG reach a price target of $6, previously predicting the price at $29. The rating they have provided for PASG stocks is “Neutral” according to the report published on January 19th, 2022.
Raymond James gave a rating of “Outperform” to PASG, setting the target price at $29 in the report published on July 01st of the previous year.
PASG Trading at -14.30% from the 50-Day Moving Average
After a stumble in the market that brought PASG to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -35.25% of loss for the given period.
Volatility was left at 9.67%, however, over the last 30 days, the volatility rate increased by 8.56%, as shares sank -16.06% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +13.86% upper at present.
During the last 5 trading sessions, PASG fell by -14.18%, which changed the moving average for the period of 200-days by +28.12% in comparison to the 20-day moving average, which settled at $1.3097. In addition, Passage Bio Inc saw 14.76% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PASG starting from Forman Mark S, who sale 1,638 shares at the price of $0.97 back on Feb 13 ’24. After this action, Forman Mark S now owns 48,631 shares of Passage Bio Inc, valued at $1,589 using the latest closing price.
Borthwick Kathleen, the SVP, INTERIM CFO of Passage Bio Inc, sale 1,470 shares at $0.97 during a trade that took place back on Feb 13 ’24, which means that Borthwick Kathleen is holding 28,466 shares at $1,426 based on the most recent closing price.
Stock Fundamentals for PASG
The total capital return value is set at -0.81. Equity return is now at value -65.29, with -51.80 for asset returns.
Based on Passage Bio Inc (PASG), the company’s capital structure generated 0.19 points at debt to capital in total, while cash flow to debt ratio is standing at -2.98. The debt to equity ratio resting at 0.24. The interest coverage ratio of the stock is 70.15.
Currently, EBITDA for the company is -96.42 million with net debt to EBITDA at -0.04. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.22.
Conclusion
In conclusion, Passage Bio Inc (PASG) has had a mixed performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
